

jc997 U.S. PTO
09/965796
10/01/01



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David M. GOLDENBERG

Title: IMMUNOTHERAPY OF B-CELL
MALIGNANCIES USING ANTI-
CD22 ANTIBODIES

Appl. No.: Unassigned

Filing Date: October 1, 2001

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

Applicant submits herewith on Form PTO-1449 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/307,816, filed May 10, 1999. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

jc997 U.S. PTO
09/965796
10/01/01

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date Oct. 1, 2001
FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5427
Facsimile: (202) 672-5399

By Bernhard D. Saxe
Bernhard D. Saxe
Attorney for Applicant
Registration No. 28,665

Form PTC-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 018733/1060	SERIAL NO. Unassigned
INFORMATION DISCLOSURE CITATION Submitted October 1, 2001 (Use several sheets if necessary)		APPLICANT		S- 97/965796 09/01781	
		FILING DATE October 1, 2001		GROUP ART UNIT Unassigned	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	5,686,072	02/1994	Uhr et al.			
	A2	5,484,892	01/1996	Tedder et al.			
	A3	5,686,072	11/11/97	Uhr et al.			

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
	A4	EP 510 949 A2	04/1992	Europe				
	A5	WO 95/09917	04/1995	WO				
	A6	WO 98/42378	01/1998	WO				
	A7	WO 99/02567	01/1999	WO				
	A8	WO 96/04925	02/1996	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A9	S. Kiesel et al. "Removal of Cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement..." Leukemia Research vol. II, no. 12, 1987, pages 1119-1125					
		O. Press, "Prospects for the management on non-Hodgkin's lymphomas with monoclonal antibodies and Immunoconjugates." Cancer Journal from Scientific American, vol. 4, no. suppl. 2, July 1998.					
	A10	D. Maloney et al. "Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal Antibody (IDE-C2B8) in patients with recurrent B-cell lymphoma" Blood, vol. 84, no. 8, 1994.					
		M. Ghetie et al. "A Combination of immunotoxins and chemotherapy can cure SCID mice of Human B-Cell Tumors" The Faseb Journal, vol. 8, no. 4, 1994.					
	A11	D. Flavell et al., "Systematic Therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-Saporin Immunotoxin, is curative of human B-Cell..." Cancer Research, vol. 57, no. 21, 1997.					
		Green et al., "Antigen-specific human monoclonal antibodies from mice engineered with hum Ig heavy and light Chain YACS", Nature Genetic, vol. 7, pp. 13-21					
	A12	R. French et al., "Response of B-cell lymphoma to a combination of bispecific antibodies and saporin" Leukemia Research, vol. 20, no. 7, July 1996.					

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 018733/1060		SERIAL NO. Unassigned	
INFORMATION DISCLOSURE CITATION Submitted October 1, 2001 (Use several sheets if necessary)		APPLICANT		David M. GOLDENBERG			
		FILING DATE October 1, 2001		GROUP ART UNIT Unassigned			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A16	C. Renner et al. "Monoclonal antibodies in the treatment of non-Hodgkin's Lymphoma: recent results and Future Prospects" Leukemia, Vol. 11, no. suppl.2, April 1997.					
	A17	J. Leonard et al. "Epratuzumab, a new anti-CD22, humanized, monoclonal antibody for the therapy of non-Hodgkin's lymphoma (NHL): phase I/II trial results" Blood, vol. 94, no. 10 suppl. 1 part 1, 1999.					
	A18	Kaminski et al., "Radioimmunotherapy of B-Cell lymphoma with [131] Anti-B1 [Anti-CD20] Antibody", New England J. of Medicine 329(7): 459-465					
	A19	Vuist et al., "Potentiation by interleukin 2 of burkitt's lymphoma therapy with Anti-Pan B (Anti-CD19) monoclonal antibodies in a mouse xenotransplantation model", Cancer Research, Vol 53, pp. 819-825					
	A20	Juweid et al., "Treatment of non-hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22", Cancer Research (Suppl.) Vol. 55, pp 5899s-5907s					
EXAMINER				DATE CONSIDERED			
<p>* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.</p>							